Abstract
BackgroundAltered circulating cell-free DNA (cfDNA) levels are related to cancer development and aggressiveness. Up to now, very few studies have been performed for evaluating cfDNA content in endometrial cancer (EC).MethodsFirst, we measured cfDNA release in blood serum of EC cancer patients collected before surgery and before the beginning of any treatment by SYBR Gold assay and correlated it with tumor aggressiveness. We also assessed the relative mitochondrial cell-free DNA (cfmtDNA) content by qRT-PCR. Next, we correlated cfDNA levels with BMI, age, hypertension and inflammation markers.ResultsCfDNA levels are higher in G2 and G3 compared with G1 EC sera. A significant modulation of cfDNA content was detected in sera from patients with BMI>30 compared with those with BMI<30. We observed a further and significant alteration in cfDNA level in hypertensive patients with G2-G3, but not in G1 EC. Analysis of preoperative neutrophil-to-lymphocyte (NLR) and monocyte-to-lymphocyte (MLR) ratios suggests a contribution of the host response in the altered cfDNA levels in EC.ConclusionsOur data indicate that assessment of total and mitochondrial cfDNA levels in blood sera and the relative NLR and MLR in blood obtained from preoperative patients may help clinical management and prognosis in EC.
Highlights
Circulating cell free DNA are doublestranded molecules with low molecular weight, in the form of short fragments and/or long fragments up to 21 kb
CfDNA levels are higher in G2 and G3 compared with G1 endometrial cancer (EC) sera
Analysis of preoperative neutrophil-to-lymphocyte (NLR) and monocyte-to-lymphocyte (MLR) ratios suggests a contribution of the host response in the altered cell-free DNA (cfDNA) levels in EC
Summary
Circulating cell free DNA (cfDNA) are doublestranded molecules with low molecular weight, in the form of short fragments (between 70 and 200 base pairs in length) and/or long fragments up to 21 kb. Several decades later, elevated cell-free DNA levels were discovered in the circulation of patients with cancer [2]. CfDNA is released into circulation by various physiologic and pathologic mechanisms. Under normal physiologic www.impactjournals.com/oncotarget circumstances, apoptotic and necrotic cells are cleared by infiltrating phagocytes and cfDNA levels are relatively low. Not all cfDNA originates from cell death. Live cells spontaneously release newly synthesized DNA as part of a homeostatically regulated system [3]. Altered circulating cell-free DNA (cfDNA) levels are related to cancer development and aggressiveness. Very few studies have been performed for evaluating cfDNA content in endometrial cancer (EC)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
